Breakthrough Therapy vs Fast Track: FDA's Faster Paths Explained
Fast track and breakthrough therapy are FDA designations that speed up development for serious diseases. Fast track only needs a drug to address an unmet need. Breakthrough therapy needs early clinical data showing the drug may be substantially better than what exists, and it brings much closer help from the FDA. Priority review and accelerated approval are separate tools that speed up the review itself.
The FDA's four faster paths at a glance
| Fast track | For a serious disease with an unmet need. Can be based on lab or animal data. More meetings with the FDA and a rolling submission. |
| Breakthrough therapy | Needs early clinical evidence of a substantial improvement over existing treatment. Everything fast track gives, plus intensive FDA guidance from Phase 1 and senior FDA staff involved. |
| Priority review | Decided when the application is filed. The FDA aims to decide in 6 months instead of 10. |
| Accelerated approval | Approval based on a surrogate marker (like tumor shrinkage) that is reasonably likely to predict real benefit. The company must run a confirmatory trial afterwards. |
Breakthrough therapy vs fast track: the real difference
The bar. Fast track can be granted before a drug has been tested in people, if the disease is serious and the need is real. Breakthrough therapy needs human data, and that data has to suggest the drug beats what patients already have on an important measure.
That is why investors treat breakthrough therapy as the stronger signal. The FDA has looked at real patient results and thought they were promising enough to clear a path. It can also take the designation away if later data disappoints.
What our data shows
Across 22,234 past biotech stock-months (June 2022 to March 2026, using only what was known on each date), the two designations behaved very differently.
| Where our records showed | Rose 50%+ / fell 30%+ in 6 months |
| Breakthrough therapy (716 stock-months, 59 companies) | 17.3% / 11.0% |
| Fast track (1,002 stock-months, 90 companies) | 15.6% / 24.0% |
| Priority review (600 stock-months, 38 companies) | 10.7% / 14.8% |
| All biotechs | 13.3% / 24.4% |
Breakthrough therapy companies fell 30% or more less than half as often as the average biotech. Fast track barely moved the numbers. Priority review came with fewer crashes but also fewer big wins, which makes sense: by the time a drug gets it, it is late-stage and much of the good news is already in the price.
Priority review vouchers
A priority review voucher lets its owner turn any future standard review into a 6-month priority review. Companies earn them by getting certain drugs approved, for rare pediatric diseases, tropical diseases or medical countermeasures, and they can sell them.
For a small biotech, a voucher can be real money. Sales in 2025 and early 2026 went for $150 million to $200 million each. The rare pediatric disease program lapsed at the end of 2024, and Congress renewed it in February 2026, through September 2029.
Accelerated approval: faster, with strings attached
Accelerated approval gets a drug to patients sooner, but it comes with a promise to prove real benefit in a confirmatory trial. If that trial fails, the FDA can pull the approval, and since a 2022 law it has had an easier path to do so. For investors, an accelerated approval is a real product with a question mark still attached.
See it live: See upcoming FDA decisions for expedited drugs, with cash, insider activity and short interest in the same row.
Open the FDA Calendar →Frequently asked questions
Fast track only requires that a drug addresses an unmet need in a serious disease, and it can be granted on lab or animal data. Breakthrough therapy requires early clinical evidence that the drug may be substantially better than existing treatment, and it adds intensive FDA guidance and senior FDA involvement on top of the fast track benefits.
No. It speeds up development and review, but the drug still has to succeed in trials and win approval. The FDA can also rescind the designation if later data disappoints.
The FDA aims to decide within 6 months, against 10 months for a standard review, counted from when it accepts the filing.
Recent sales were between $150 million and $200 million. The highest price on record is $350 million, paid in 2015.
Yes. A drug can have orphan drug, fast track and breakthrough therapy designations at once, and later receive priority review or accelerated approval.
Educational content only. Not financial advice. Past results don't predict future ones.